Haupt Axel, Thamer Claus, Machann Jürgen, Kirchhoff Kerstin, Stefan Norbert, Tschritter Otto, Machicao Fausto, Schick Fritz, Häring Hans-Ulrich, Fritsche Andreas
Department of Internal Medicine, Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Eberhard-Karls-University of Tübingen, Tübingen, Germany.
Obesity (Silver Spring). 2008 Aug;16(8):1969-72. doi: 10.1038/oby.2008.283. Epub 2008 May 29.
Polymorphisms in the fat mass- and obesity-associated (FTO) gene have been identified to be associated with obesity and diabetes in large genome-wide association studies. We hypothesized that variation in the FTO gene has an impact on whole body fat distribution and insulin sensitivity, and influences weight change during lifestyle intervention. To test this hypothesis, we genotyped 1,466 German subjects, with increased risk for type 2 diabetes, for single-nucleotide polymorphism rs8050136 in the FTO gene and estimated glucose tolerance and insulin sensitivity from an oral glucose tolerance test (OGTT). Distribution of fat depots was quantified using whole body magnetic resonance (MR) imaging and spectroscopy in 298 subjects. Two-hundred and four subjects participated in a lifestyle intervention program and were examined after a follow-up of 9 months. In the cross-sectional analysis, the A allele of rs8050136 in FTO was associated with a higher BMI, body fat, and lean body mass (all P < 0.001). There was a significant effect of variation in the FTO gene on subcutaneous fat (P < or = 0.05) and a trend for liver fat content, nonvisceral adipose tissue, and visceral fat (all P < or = 0.1). However, the single-nucleotide polymorphism was not associated with insulin sensitivity or secretion independent of BMI (all P > 0.05). During lifestyle intervention, there was also no influence of the FTO polymorphism on changes in body weight or fat distribution. In conclusion, despite an association with BMI and whole body fat distribution, variation in the FTO locus has no effect on the success of a lifestyle intervention program.
在大规模全基因组关联研究中,已确定脂肪量和肥胖相关(FTO)基因的多态性与肥胖和糖尿病有关。我们推测,FTO基因的变异会影响全身脂肪分布和胰岛素敏感性,并影响生活方式干预期间的体重变化。为了验证这一假设,我们对1466名2型糖尿病风险增加的德国受试者进行了FTO基因单核苷酸多态性rs8050136的基因分型,并通过口服葡萄糖耐量试验(OGTT)评估了葡萄糖耐量和胰岛素敏感性。在298名受试者中,使用全身磁共振(MR)成像和光谱法对脂肪储存分布进行了量化。204名受试者参加了生活方式干预计划,并在随访9个月后接受了检查。在横断面分析中,FTO中rs8050136的A等位基因与较高的体重指数、体脂和瘦体重相关(所有P<0.001)。FTO基因变异对皮下脂肪有显著影响(P≤0.05),对肝脏脂肪含量、非内脏脂肪组织和内脏脂肪有一定趋势(所有P≤0.1)。然而,单核苷酸多态性与独立于体重指数的胰岛素敏感性或分泌无关(所有P>0.05)。在生活方式干预期间,FTO多态性对体重或脂肪分布的变化也没有影响。总之,尽管与体重指数和全身脂肪分布有关,但FTO基因座的变异对生活方式干预计划的成功没有影响。